Risk Stratification
Combination Testing With ThyGeNEXT and ThyraMIR Provides Accurate Reclassification1
ThyGeNEXT + ThyraMIR Combination Testing Performance1
High NPV
- Significant decrease in unnecessary surgeries
- 85% reduction relative to cytology alone (P<0.01)
Testing helps to risk-stratify the need for or extent of surgery needed
ATA and NCCN Guidelines support testing for nodules with a B-III or B-IV cytology diagnosis
50 %
Sensitivity
50 %
NPV
50 %
Specificity
40 %
PPV
Markers
Strategically Designed Panel for the Optimal Management of Thyroid Nodules
| ThyGeNEXT® NGS Panel | ThyraMIR® miRNA classifier | |
| DNA mutation panel | RNA panel (# fusions) | |
| ALK | ALK (2) | miR-29b-1-5p |
| BRAF | BRAF (3) | miR-31-5p |
| GNAS | NTRK (8) | miR-138-1-3p |
| HRAS | PPARg (5) | miR-139-5p |
| KRAS | RET (14) | miR-146b-5p |
| NRAS | THADA (5) | miR-155 |
| PIK3CA | mRNA markers: NKX2-1, PAX8, TBP, USP33 | miR-204-5p |
| PTEN | miR-222-3p | |
| RET | miR-375 | |
| TERT | miR-551b-3p | |
Newly added TERT and ALK mutations can reliably help to predict aggressive biological features of thyroid cancer, including:
- Large tumor size
- Higher patient mortality
- Likelihood of lymph node metastasis
- Higher rate of recurrence post-treatment
- Higher clinical stage at time of cancer detection
- Likelihood of cancer spreading beyond the thyroid
- Increased risk for tumor vascular invasion
- Potential for treatment failure
Long-Term Evidence
Impact of BRAF V600E or TERT C288T Alone or Their Coexistence on Disease-free Survival of Patients With PTC2
Coexisting BRAF V600E and TERT C228T mutations form a novel genetic background that defines PTC with the potentially worst clinicopathologic outcomes, providing unique prognostic and therapeutic implications.
References
- Labourier, et al, Journal Clinical Endocrinology Metabolism 100: 2743, 2015
- Xing M et al., BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence, Journal of Clinical Oncology 2014
